💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Alpa Laboratories Limited is an India-based global pharmaceutical company engaged in manufacturing and selling finished pharmaceutical dosage forms. Its product range includes a variety of ethical, generic, and over the counter (OTC) drugs in various finished dosage forms for…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A middling, slow-growing business, trading cheap versus its own history — but flagged on governance.
Alpa Laboratories is scored on the pharma / healthcare framework. It keeps a healthy 12.3% of every rupee of sales as net profit. Cash conversion lags the reported profit (CFO/PAT 0.62×) — worth a closer look. Free cash flow is worth about -1.5% of its market value.
Over the last 3 years revenue compounded at 6%/yr and profit at 6%/yr. Book value has grown 11%/yr. Return on equity is a modest 8.1%. In the latest quarter profit fell 29% versus the prior quarter.
At 8× earnings, the stock sits at the 9th percentile of its own 3.6-year range — the cheap end of where it has historically traded. Today's price implies ~13%/yr earnings growth for a decade. The forensic screen raises a red flag: 94% of pre-tax profit is other income, not operations.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 26.42 | — | — |
| P/B | 0.58 | — | — |
| EV/EBITDA | 13.46 | 19.33 | better |
| ROE | 8.06 | — | — |
| ROCE | 8.98 | 14.41 | worse |
| ROA | 1.68 | 1.64 | better |
| Quick Ratio | 3.76 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue is on a 2-year growth streak. 6% CAGR — growing but slowly. Growth is decelerating — latest year grew slower than the year before.
Profit is on a 2-year growth streak.
Operating margin has compressed from 16% to 14% — costs or competition are eating into profitability.
ROE at 8% — modest; the capital isn't working hard. Low variance across years — a predictable business that earns steadily on its equity base.
EPS dropped in the latest year despite possible profit changes — dilution or a profit dip could be at play. 4% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Raising capital despite positive cash flow — could signal expansion plans or opportunistic fundraising.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue broadly flat QoQ — stable but not accelerating. Low quarterly variance (6% spread) — a predictable, non-seasonal revenue stream.
Profit fell 29% QoQ — one-quarter drops can be noise, but a pattern matters. Quarterly net margins are expanding (0% → 3%) — profitability per rupee of revenue is improving.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoter holding at 57.2% — majority control intact.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.